Lipid Profile Alterations Across Coronary Heart Disease, Metabolic Syndrome, and Nephrotic Syndrome.

Shudong Tan; Tianji Qu; Jing Ai; Yaoyang Fu

doi:10.1002/jcla.70189

March 5, 2026

Lipid Profile Alterations Across Coronary Heart Disease, Metabolic Syndrome, and Nephrotic Syndrome.

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to identify dyslipidemia patterns and their relevance in diagnosing CHD, MetS, and NS.
Observed lipid profiles in patients with CHD, MetS, and NS.
Analyzed TC, sdLDL-C, and ApoB levels for diagnostic potential.
Investigated disease-specific variability in lipid markers.
Dyslipidemia patterns vary significantly across CHD, MetS, and NS.
TC and sdLDL-C emerged as robust markers for CHD.
ApoB showed variability that indicates it may have diagnostic potential.

Implication

Distinct dyslipidemia patterns found in CHD, MetS, and NS, highlighting the need for accurate lipid profiling and risk stratification.

Abstract

Distinct patterns of dyslipidemia were observed in CHD, MetS, and NS. TC and sdLDL-C might serve as robust markers for CHD, while ApoB demonstrated disease-specific variability with diagnostic potential. These findings underscored the importance of detailed lipid profiling for improved risk stratification and targeted management.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tan et al. (2026) studied this question.

synapsesocial.com/papers/69acc5b032b0ef16a40505f7 https://doi.org/10.1002/jcla.70189

View at Publisher

Ask AI

Bookmark

Share

Lipid Profile Alterations Across Coronary Heart Disease, Metabolic Syndrome, and Nephrotic Syndrome.

Key Points

Implication

Abstract

Discussion

Cite This Study

Lipid Profile Alterations Across Coronary Heart Disease, Metabolic Syndrome, and Nephrotic Syndrome.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading